Merrill Lynch Stick to Their Buy Rating for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, which is approximately 9.11 % above the present share price of $76.07.

Cherny expects CVS Health Corp to submit earnings per share (EPS) of $0.93 for the earliest quarter of 2021.

The current consensus among eleven TipRanks analysts is for a reasonable Buy rating of shares in CVS Health, with an average price target of eighty four dolars.

The analysts price targets range from a high of hundred one dolars to a low of $61.

From its newest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net profit of $3.25 billion. The company’s market cap is $99.57 billion.

According to TipRanks.com, Merrill Lynch analyst Michael Cherny is now ranked with four stars on a 0 5 stars ranking scale, with an average return of 11.5 % along with a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It runs through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions. The retail or Long Term Care segment has offering of prescription drugs and assortment of general merchandise.

The Health Care Benefits segment offers traditional, voluntary and consumer-directed health insurance products as well as associated services, including medical, pharmacy, dental, behavioural health, medical control abilities. The Corporate segment involves in providing management as well as administrative services. The company was created by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.